A new Longevity.Technology report pairs Nature Aging economic modelling with its own market forecast, estimating that adding ten years to US life expectancy would generate $366.8 trillion in societal value against roughly $3.3 trillion in therapeutic spending over a decade. The resulting 100x multiple describes value distributed across an economy — productivity, tax receipts, reduced late-life care burden — rather than returns captured by investors. The gap between public benefit and private capture explains why preventive interventions remain chronically underfunded relative to their worth.
Key Points
- Ten added life-expectancy years valued at $366.8 trillion for US economy
- Societal return reaches 100x; annual market-to-value ratio nearer 22x
- Model assumes 2035 approval, GLP-1 pricing, 35% eligible uptake
Longevity Analysis
The economics confirm what practitioners observe clinically: interventions that delay functional decline produce value that no single invoice captures, which is precisely why they attract less capital than acute care. For individuals, the asymmetry argues for acting ahead of the market — removing the exposures and habits that accelerate decline, and sustaining the daily practices that preserve metabolic capacity, tissue repair and resilience, rather than waiting for a gerotherapeutic to arrive priced at GLP-1 levels in 2035. The figures also carry heavy assumptions about approval timelines, pricing and uptake; the magnitude of the societal case matters more than the precision of the multiple.
Original published by Longevity.Technology, by Eleanor Garth.